MAIA Biotechnology updates on Phase 3 ateganosine trial in NSCLC; Fast Track status

MAIA Biotechnology, Inc.

Ongoing Phase 3 full approval trial of ateganosine for third-line non-small cell lung cancer.
FDA Fast Track designation provides clear regulatory pathway for ateganosine.
First and only direct telomere-targeting anticancer agent in clinical development.
Targets ~50,000 US patients annually in 3L NSCLC with no established standard of care.
CEO Vlad Vitoc cites $50 billion global immunotherapy market opportunity in letter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.